KRAS mutation predicts unfavorable clinical outcomes in pancreatic ductal adenocarcinoma patients who were treated with first-line gemcitabine-based chemotherapy.
구분
국외
국가
미국
컨퍼런스명
AACR 102nd Anuual Meeting
발표 제목
KRAS mutation predicts unfavorable clinical outcomes in pancreatic ductal adenocarcinoma patients who were treated with first-line gemcitabine-based chemotherapy.